Epithalon (Epitalon)

Epithalon (also spelled Epitalon) is a synthetic four-amino-acid peptide with the sequence Ala-Glu-Asp-Gly (AEDG). It was developed by Russian gerontologist Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology as the proposed active fragment of "epithalamin," a peptide extract of the pineal gland. It is studied as a "peptide bioregulator" in the context of aging biology, circadian rhythm, and cellular senescence. It is an experimental research compound, not an approved drug or a dietary supplement ingredient.

Education only. This page summarises published research and regulatory status. It is not medical advice and gives no dosing, preparation or administration instructions; any decision about use belongs with an independent qualified professional.

Also known as: Epitalon, Epithalone, AEDG peptide, Ala-Glu-Asp-Gly, Synthetic epithalamin, Epithalamin (the natural pineal extract it was derived from)
Class: Synthetic pineal tetrapeptide / putative telomerase activator (bioregulator peptide)

How does Epithalon work?

The leading proposed mechanism is activation of telomerase — specifically increased expression of the telomerase catalytic subunit (hTERT) — which in cultured human fibroblasts was reported to lengthen telomeres and allow cells to keep dividing beyond the normal Hayflick limit. Additional proposed mechanisms include epigenetic effects (binding short DNA sequences, chromatin decondensation, and altered expression of genes such as those in antioxidant/Nrf2 pathways), stimulation of pineal melatonin synthesis and circadian/cortisol normalization, and modulation of immune signaling (e.g., interleukin-2). Importantly, reviewers note it remains uncertain whether these are the true or sole mechanisms in living humans, and most mechanistic data come from cell-culture and animal models.

What has Epithalon been studied for?

Telomere maintenance / telomerase activation in cultured human cells
Cellular and organismal aging / lifespan extension (rodents, fruit flies, primates)
Circadian rhythm and melatonin/cortisol normalization
Retinitis pigmentosa (small human and animal studies)
Antioxidant defense and oxidative-stress reduction
Tumor incidence reduction in cancer-prone animal models
Immune function and neuroprotection (preclinical)

What does the evidence show?

Evidence is preliminary and skewed heavily toward in-vitro and animal work, much of it from a single research group (Khavinson and colleagues in Russia), which limits independent replication. Cell-culture studies report telomerase activation and telomere elongation in human fetal fibroblasts (Khavinson et al., 2003), and animal studies (mice, rats, Drosophila, some primates) report lifespan effects, reduced tumor incidence, antioxidant changes, and melatonin/circadian normalization in aged animals. Human data are minimal: small open-label or single-condition studies (e.g., a retinitis pigmentosa cohort and a ~75-woman circadian-rhythm study), with no large, randomized, placebo-controlled Western trials. Major caveats include probable publication bias, reliance on primary sources from one center, small or uncontrolled human studies, and the fact that telomerase activation as a plausible mechanism does NOT establish that it safely extends healthspan or lifespan in healthy people. Claims of anti-aging benefit in humans are unproven.

What is known about the safety of Epithalon?

Published research reports a relatively clean short-term safety signal: clinical research participants (e.g., the retinitis pigmentosa cohort) reported no side effects, and animal studies found no genotoxic effects and even nephroprotective effects at tested doses. However, the safety picture is incomplete and reviewers explicitly flag this as a critical gap — formal short- and long-term toxicity, genotoxicity, and carcinogenicity evaluations have not been adequately done. A theoretical concern is that telomerase activation is a mechanism shared with many cancers, so the long-term oncologic safety of repeatedly upregulating telomerase in humans is genuinely unknown. There are no controlled long-term human safety data, no established interactions profile, and quality/purity of grey-market material is unverified. It has not been evaluated for use in pregnancy, breastfeeding, or in people with cancer or cancer risk.

What is the legal status of Epithalon?

Not approved by the FDA for any use, and not an authorized dietary-supplement ingredient in the US. It is an unapproved research/experimental compound that sits in a regulatory grey zone; it is sold by some vendors as a "research chemical" or through biohacking/longevity-clinic channels, but it is not a legitimate approved medicine or consumer wellness product in the US, EU, UK, or other major jurisdictions. Most of its clinical use and study has occurred in Russia. It is not specifically a WADA-banned named substance, but athletes should treat unapproved peptides with caution. US compounding status, October 2026: on 15 April 2026 the FDA removed Epitalon from Category 2 of its interim 503A bulk-substances list, where it had been listed over safety concerns, and on 23-24 July 2026 the FDA's Pharmacy Compounding Advisory Committee voted to recommend adding it to the 503A bulks list. The vote is a non-binding recommendation, not a drug approval, and does not by itself let pharmacies compound it. On 14 October 2026 the FDA sent an “Interim Access Policy for Compounding Using Certain Peptides” to the White House Office of Information and Regulatory Affairs for review; as of 21 October 2026 its text and scope were not public and it was not in effect.

What is the half-life of Epithalon?

Not formally characterized in humans. No published human pharmacokinetic or half-life data exist. As a small unmodified tetrapeptide, AEDG is expected to be rapidly broken down by peptidases and to have a very short circulating half-life (on the order of minutes), and it has poor oral bioavailability due to enzymatic degradation — but a precise, validated half-life value has not been established in peer-reviewed human studies.

Sources

From the Peppies Peptide Intelligence Library: an educational summary of the published literature, not medical advice. No dosing, preparation or administration instructions are given on these pages. Last updated 2026-09-24. Corrections: support@peppies.eu.